Uncovering early, lineage-dependent effects of TPMT genotype in adult acute lymphoblastic leukemia by minimal residual disease Heterozygous thiopurine methyltransferase (TPMT)-genotype conferring lower TPMT activity has been shown to be a favorable prognostic factor in acute lymphoblastic leukemia (ALL) presumably due to its modulation of mercaptopurine dose intensity. 1, 2 We investigated whether this association was also measurable by minimal residual disease (MRD) in adult ALL patients as has been suggested for childhood ALL. 3 Over 20 allelic variants with single nucleotide polymorphisms (SNPs) of the TPMT gene have been described, leading to a trimodal distribution of TPMT activity 4 with heterozygous individuals (6-11% of caucasians) having markedly reduced and homozygous individuals (0.2-0.6% of caucasians) having virtually undectable TPMT activity. 3, 5 TPMT-genotype is considered to be one of the few pharmacogenomic tests that has successfully made the transition from bench to bedside and so far is the only example of pharmacogenetic-based drug dosing in ALL. 6 Nevertheless, discrepant results between studies that are discussed later in this manuscript indicate the need of more Accepted article preview online 27 September 2012; advance online publication, 23 October 2012
Letters to the Editor detailed information regarding the role of TPMT-genotype in relation to specific therapeutic elements, some of which may be provided by MRD analysis.
TPMT-genotype and MRD were determined in 494 patients with standard risk adult ALL treated within the GMALL 06/99 and 07/03 trials. They were therefore devoid of either clinical (leukocyte count 430,000/ml at presentation in precursor B-ALL, no complete remission (CR) after induction phase I), immunologic (pro-B, pre-T and mature T-ALL), or cytogenetic risk factors (t(9;22) and translocations involving the MLL-gene)). MRD-based risk stratification was part of the study protocol and MRD was thus measured routinely during therapy. Conversely, TPMT-genotype did not influence the risk stratification and was determined from leftover material. The patients' informed consent was obtained at the time of entry into the trials according to the declaration of Helsinki. GMALL studies 06/99 and 07/03 were approved by the institutional review board of the University of Frankfurt and are registered at clinicaltrials.gov (NCT00199056, NCT00198991). Baseline characteristics of the patients were not different according to TPMT-genotype (see Table 1 ).
Patients received treatment consisting of an induction, reinduction, and six cycles of consolidation therapy lasting one year based on the drugs dexamethasone, cyclophosphamide, vincristine, daunorubicin, methotrexate (MTX), asparaginase, cytosine arabinoside, 6-mercaptopurine (6-MP) and etoposide. The recommended maintenance therapy consisted of six consolidation cycles during the second year of therapy similar to the ones given during the first year with intermediary application of 6-MP and MTX. MRD analysis was performed routinely according to the study protocol before induction II and consolidation I, and optionally during induction I and after induction II using real-time quantitative PCR of rearranged immune-gene targets. 7 MRD results including MRD negativity were interpreted according to the guidelines and quality control measures of the Euro MRD-group (former ESG-MRD-ALL). 8 The primer sets for the PCR-reactions for determination of TPMT-genotype screened for the TPMT G460A and TPMT A719G mutations, which correctly identifies at least 96% of all patients and the large majority of genotypes with low TPMT activity. WBC at diagnosis (median, range/ml) Precursor B cell 4500 (600-29400) 4400 (600-29400) 6300 (1000-25500) À 2800 to 2700 T cell 41200 (1640-731100) 40800 (1640-731100) 50000 (12600-252000) À 49000 to 70000
Abbreviations: CI, confidence interval; TPMT-genotype, thiopurine methyltransferase genotype; WBC, white blood cell. Figure 1 . MRD-status before and after 6-MP according to immunologic subtype and TPMT-genotype.
distribution of risk factors between groups was assumed if the confidence interval of differences of means or proportions included zero. Overall survival (OS) was defined as the time from study entry to death or last patient contact. Relapse free survival (RFS) and event free survival were defined from date of CR to date of relapse or last contact in continuous CR or death, respectively. Survival times were compared by log-rank test. For all statistical comparisons a two-sided P-value p0.05 was considered to be statistically significant.
For patients who remained event-free, the median observation time was 49.0 months. 5-year OS of the total cohort was 64.8% (95% CI, 60.0-70.0%), 5-year RFS was 54.3% (95% CI, 49.0-60.2%). When analyzed according to immunophenotype, for the patients with precursor B-ALL 5-year OS was 63.7% (95% CI, 57.5-70.5%) and 5-year RFS was 50.5% (95% CI, 43.7-58.4%) whereas for the patients with T-ALL it was 66.7% (95% CI, 59.3-75.2%) and 60.4% (95% CI, 52.6-69.3%), respectively, with no statistically different OS and RFS between the two groups (P ¼ 0.60 for OS and P ¼ 0.55 for RFS). There was no statistical evidence for a Hardy-Weinberg disequilibrium of the allele frequencies. Frequencies of different TPMT genotypes were as follows: *1/*1 464/494 (93.9%), *1/*3A 24/494 (4.9%), *1/*3B 2/494 (0.4%), and *1/*3C 4/494 (0.8%). The presence of a polymorphism associated with reduced TPMT activity was associated with a tendency towards a better RFS (wild-type: 49.2% (95% CI, 42.1-57.4%), heterozygous: 69.9% (95% CI, 50.5-96.6%), P ¼ 0.27) and OS (wild-type: 62.3% (95% CI, 55.9-69.3%), heterozygous: 87.2% (95% CI, 71.9-100.0%), P ¼ 0.15) in precursor B-ALL, but not in T-ALL (5-year RFS, wildtype: 59.7% (95% CI, 51.7-69.0%), heterozygous: 72.9% (95% CI, 46.8-100.0%), P ¼ 0.58, 5-year OS, wild-type: 66.3% (95% CI, 58.6-75.0%), heterozygous: 72.9% (95% CI, 46.8-100.0%), P ¼ 0.7).
MRD measurement before (day 11 and 26) and after (day 46 and 71) mercaptopurine treatment allowed for determination of its effects on MRD. Patients with precursor B-ALL and non wildtype TPMT-genotype were MRD-negative already before 6-MP administration in a significant higher number than wild-type patients (58.8% of mutated vs 31.7% of wild-type, P ¼ 0.043). Due to the already high percentage of MRD negativity in non wild-type patients, this difference was less striking after application of 6-MP (76.5% vs 60.0%, P ¼ 0.28). No differences in MRD kinetics according to TPMT-SNPs were observed for patients with T-ALL (rate of MRD negativity: day 11/26 16.7% vs 35.3%, P ¼ 0.62, day 46/71: 100.0% vs 79.9%, P ¼ 0.49, see Figure 1 ).
The results indicating that a genotype low TPMT activity is associated with a steep early MRD decrease in B-cell precursor ALL come unexpected as the better outcome in those patients has always been attributed to higher 6-MP dose intensity. In our study, however, individuals with precursor B-ALL and mutant TPMT genotypes not only had a tendency towards a better outcome, but also they already were MRD negative in a significant higher proportion before the first application of 6-MP. While an earlier study in childhood ALL did not show statistically significant difference between TPMT-genotypes before application of 6-MP, 3 there also was a tendency towards a steeper initial reduction of tumor load as evidenced by the prednisone response, where only 2/53 (3.8%) heterozygous individuals for which information was available were prednisone poor responders as opposed to 79/671 (11.8%) in the homozygous group.
The observed influence of the TPMT-genotype on MRD in patients with precursor B-ALL before application of mercaptopurines suggests a direct connection to the physiological role of TPMT, which is currently known just as little as its endogenous substrate. TPMT activity in red blood cells, which correlates with activity in leukemic blasts, 9 has been found to be increasing in patients with ALL from diminished levels at diagnosis to significantly increased levels after mercaptopurine-free induction therapy. 10 TPMT catalyzes methylation of mercapto residues in aromatic and heterocyclic compounds using S-adenosylmethionine (SAM) as a methyl donor thereby generating S-adenosylhomocysteine (SAH), a reaction similar to that performed by DNA methyltransferases (DNMTs). As SAM is the only known methyl donor for DNA methylation and SAH has been shown to inhibit DNMTs, TPMT activity might decrease DNA methylation by lowering TPMT activity with consequently less consumption of SAM and less production of SAH. This is suggested by a study in a cell line with inducible TPMT, which showed that not SAM depletion but DNMT inhibition by non-TPMT-metabolized metabolite(s) of 6-MP and thioguanine was responsible for a decrease in DNMT levels and global DNA methylation. 11 A lower TPMT activity thus would lead to a higher concentration of yet unknown endogenous and-during chemotherapy with mercaptopurines-exogenous non-TPMT-metabolized inhibitors of DNMTs in leukemic blasts. Interestingly, this is currently one of the most actively pursued strategies in drug development to reactivate expression of silenced genes in hematological malignancies. 12 While the mechanism of action is still to be shown, differences in outcome according to TPMT-genotype in precursor B-ALL patients may therefore not only be related to differences in metabolism of mercaptopurine chemotherapeutics. While currently admittedly based on a limited number of patients, this conclusion is strongly supported by clinical studies in childhood ALL showing a relationship between mercaptopurine metabolism or TPMT-genotype and risk of relapse, 1,2 but failing to improve outcome by intervention, 13 generally considered to be the gold standard for this kind of question. On the basis of these data, inhibition of TPMT early during therapy might be a promising approach in the future.
Furthermore, these results contribute to the increasing acceptance of the understanding that genetic tests identify a number of subgroups far to large to be tested individually in clinical trials because of the lack of sufficient numbers of patients.
14 Taken together with the problem to predict clinical benefits based on preclinical data or phase I and II studies alone, the benefit of using MRD as a biomarker that integrates pretherapeutic risk factors with disease and host factors through assessing response to therapy is increasingly acknowledged.
